19,900 Shares in TG Therapeutics, Inc. $TGTX Bought by Strs Ohio

Key Points

• Strs Ohio acquired a new investment position in TG Therapeutics, purchasing 19,900 shares valued at approximately $785,000 in the first quarter.
• The company reported $0.17 earnings per share, which missed analysts' expectations of $0.32, although revenue rose 92.1% year-over-year to $141.15 million.
• Analysts have given TG Therapeutics a consensus rating of "Moderate Buy" with a target price of $48.00, indicating optimism about the stock's future performance.

Strs Ohio acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 19,900 shares of the biopharmaceutical company's stock, valued at approximately $785,000.

Other institutional investors have also modified their holdings of the company. Vermillion Wealth Management Inc. acquired a new position in shares of TG Therapeutics in the fourth quarter valued at approximately $30,000. NBC Securities Inc. grew its holdings in TG Therapeutics by 82,300.0% in the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 823 shares during the period. Golden State Wealth Management LLC grew its holdings in TG Therapeutics by 100.0% in the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 433 shares during the period. SVB Wealth LLC purchased a new stake in TG Therapeutics in the first quarter valued at approximately $37,000. Finally, USA Financial Formulas purchased a new stake in TG Therapeutics in the first quarter valued at approximately $57,000. Institutional investors and hedge funds own 58.58% of the company's stock.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the firm's stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the transaction, the director directly owned 94,061 shares in the company, valued at $3,032,526.64. This trade represents a 18.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 10.64% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on TGTX. B. Riley boosted their target price on shares of TG Therapeutics from $53.00 to $55.00 and gave the company a "buy" rating in a report on Wednesday, September 17th. The Goldman Sachs Group upgraded shares of TG Therapeutics to a "hold" rating and set a $37.00 price objective for the company in a research note on Thursday, July 10th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, TG Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $48.00.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX traded up $0.90 during mid-day trading on Tuesday, reaching $35.87. The company's stock had a trading volume of 156,605 shares, compared to its average volume of 2,449,703. The firm has a market capitalization of $5.69 billion, a PE ratio of 97.51 and a beta of 1.88. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96. The stock has a fifty day moving average of $31.84 and a two-hundred day moving average of $35.63. TG Therapeutics, Inc. has a 52 week low of $21.16 and a 52 week high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business had revenue of $141.15 million during the quarter, compared to the consensus estimate of $147.76 million. During the same period last year, the company earned $0.04 EPS. The business's revenue was up 92.1% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.